Record venture investment is driving new biotech companies in Australia to accelerate research, clinical development, and global partnerships.
Record venture investment is driving new biotech companies in Australia to accelerate research, clinical development, and global partnerships.
Landmark clinical results suggest preventative therapy could delay or halt Alzheimer’s onset in high-risk individuals, reshaping the outlook …
Two key players in immunology and vaccine innovation gain financial momentum as they push forward with mRNA vaccines …
Roche introduces an ultra-rapid and scalable next-generation sequencing method poised to accelerate genomic research and potentially reshape clinical …
The TROPION-Breast01 phase III study shows that while the ADC datopotamab deruxtecan (Dato-DXd) improves progression-free survival, it does …
A pioneering personalized cancer vaccine, designed using tumor-specific neoantigens, has achieved remission in all nine advanced kidney cancer …
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) modernizes its clinical trial framework with major updates to …
Uvax Bio elevated Chief Business Officer Kevin O’Neill to Interim CEO following the departure of Ji Li, Ph.D., …
Novartis confirmed its acquisition of Anthos Therapeutics for up to $3.1 billion—securing a promising Phase III-stage anticoagulant aimed at …
Atalanta Therapeutics raises $97 million in Series B funding to accelerate RNA interference therapies into Phase 1 trials, …
Already a subscriber? Log in